The FDA on December 21, 2018 approved ELZONRISĀ®, a CD123-directed cytotoxin, for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRISĀ® is a product of Stemline Therapeutics.
Other Pages – Bottom Ad
Advertisement
Subscribe
